Sernova Corp. is a Canadian-based clinical-stage biotechnology firm that’s growing its Cell Pouch System.
It is a novel implantable and scalable medical system with immune protected therapeutic cells, for the remedy of persistent illnesses resembling insulin-dependent diabetes, thyroid illness, and blood issues that embody hemophilia A.
On implantation, the Cell Pouch types a pure vascularized tissue surroundings within the physique for the long-term survival and performance of therapeutic cells that launch important elements absent or poor in sufferers with sure persistent illnesses. Sernova can be advancing a proprietary expertise to protect therapeutic cells from immune system assaults with the purpose to get rid of the necessity for persistent, systemic immunosuppression.
In Might 2022, the corporate introduced a world strategic partnership with Evotec, offering Sernova with a doubtlessly limitless provide of insulin-producing islet cells to deal with sufferers with insulin-dependent diabetes (sort 1 and kind 2).
Sernova continues to progress extra improvement applications using its Cell Pouch System: a cell remedy for hypothyroid illness ensuing from thyroid gland removing and an ex-vivo lentiviral Issue VIII gene remedy for hemophilia A.
We spoke with Philip Toleikis, president and CEO of Sernova at Bio-Europe in Leipzig, Germany.
Toleikis joined Sernova in 2009. Below his management, the corporate stated it has achieved outstanding interim ends in its ongoing section 1/2 sort 1 diabetes (T1D) scientific trial, expanded the capabilities of its CPS platform through expertise acquisitions, and considerably bolstered its steadiness sheet.
The corporate is presently on the lookout for a brand new CEO as Toleikis will transition to turn out to be the chief expertise officer.